Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effect of Morus Nigra Mouthwash on Gingivitis Treatment

NCT07499596 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-01-15
Last updated
2026-04-13

Condition(s) studied

Gingivitis

Investigational drug(s) / intervention(s)

Scaling and Root PlaningMorus Nigra Mouthwash

Scaling and Root Planing: Mechanical removal of dental plaque and calculus from the tooth surfaces

Morus Nigra Mouthwash: Morus nigra extract based mouthwash, used 2 times a day for 14 days

Study summary

The aim of this study is to evaluate the clinical, microbiological, and biochemical effects of Morus nigra (black mulberry) mouthwash when used as an adjunct to non-surgical periodontal treatment (scaling and root planing - SRP) in patients with generalized gingivitis. Participants will be randomly assigned to two groups: one receiving SRP only, and the other receiving SRP plus Morus nigra mouthwash twice daily for 14 days. Clinical parameters, cytokine levels in gingival crevicular fluid (TNF-alpha, IL-1beta, IL-10), and subgingival bacterial load will be assessed at baseline, 1 month, and 3 months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of generalized gingivitis (Gingival Index \> 1). * Presence of at least 20 natural teeth. * Systemically healthy individuals. * Ability to provide informed consent. Exclusion Criteria: * Smoking or use of tobacco products. * Presence of periodontitis (no clinical attachment loss). * Use of antibiotics or anti-inflammatory drugs in the last 6 months. * Pregnancy or lactation. * History of allergy to Morus nigra or mouthwash components. * Systemic diseases (Diabetes, cardiovascular diseases, etc.).

Primary outcome measure(s)

  • Changes in Gingival Index (GI) — Baseline, 1 month, and 3 months.
    Gingival inflammation will be assessed using the Loe and Silness Gingival Index. Higher scores indicate more severe inflammation.

Trial sites (1)

FacilityCityRegionStatus
Inonu University Faculty of Dentistry Battalgazi Malatya Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07499596 on ClinicalTrials.gov ↗ ← All trials in Turkey